We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

151 hedge funds and large institutions have $157M invested in Acorda Therapeutics in 2019 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 42 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 42

7% less funds holding

Funds holding: 163 → 151 (-12)

33% less call options, than puts

Call options by funds: $810K | Put options by funds: $1.2M

37% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 30

65% less capital invested

Capital invested by funds: $451M → $157M (-$294M)

Holders
151
Holders Change
-12
Holders Change %
-7.36%
% of All Funds
3.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
57
Reduced
42
Closed
30
Calls
$810K
Puts
$1.2M
Net Calls
-$390K
Net Calls Change
-$1M

Top Buyers

1
PHS
PFM Health Sciences
California
+$9.9M
2
BlackRock
BlackRock
New York
+$3.75M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.69M
4
AQR Capital Management
AQR Capital Management
Connecticut
+$1.99M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.93M

Top Sellers

1
State Street
State Street
Massachusetts
-$11.1M
2
PA
Perceptive Advisors
New York
-$8.65M
3
Prudential Financial
Prudential Financial
New Jersey
-$2.91M
4
Teacher Retirement System of Texas
Teacher Retirement System of Texas
Texas
-$2.74M
5
SCM
Scopia Capital Management
New York
-$2.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$22.5M +$3.75M +6,899 +12%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$20.5M +$73.4K +135 +0.2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$17.2M -$978K -1,800 -3%
Renaissance Technologies
4
Renaissance Technologies
New York
$11.6M -$2.27M -4,180 -11%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$9.04M -$1.07M -1,971 -7%
SCM
6
Scopia Capital Management
New York
$7.96M -$2.49M -4,580 -17%
BBA
7
Baker Bros. Advisors
New York
$6.41M +$1M +1,845 +11%
PHS
8
PFM Health Sciences
California
$6.28M +$9.9M +18,219 New
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$4.21M +$1.49M +2,747 +29%
State Street
10
State Street
Massachusetts
$4.06M -$11.1M -20,360 -63%
Northern Trust
11
Northern Trust
Illinois
$2.92M +$117K +215 +3%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$2.9M +$2.69M +4,947 +143%
Jacobs Levy Equity Management
13
Jacobs Levy Equity Management
New Jersey
$2.84M +$1.93M +3,548 +76%
FAM
14
Fred Alger Management
New York
$2.29M -$203K -374 -5%
AQR Capital Management
15
AQR Capital Management
Connecticut
$1.94M +$1.99M +3,666 +186%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.62M -$337K -620 -12%
Norges Bank
17
Norges Bank
Norway
$1.44M -$2M -3,682 -47%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$1.38M +$544 +1 +0%
Russell Investments Group
19
Russell Investments Group
United Kingdom
$1.3M +$883K +1,625 +78%
Ameriprise
20
Ameriprise
Minnesota
$1.22M +$541K +995 +39%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$1.12M +$171K +314 +11%
Principal Financial Group
22
Principal Financial Group
Iowa
$1.11M +$265K +488 +18%
Goldman Sachs
23
Goldman Sachs
New York
$1.07M -$819K -1,507 -33%
Diamond Hill Capital Management
24
Diamond Hill Capital Management
Ohio
$1.05M -$558K -1,027 -25%
Invesco
25
Invesco
Georgia
$1.04M +$134K +247 +9%
1
2 3 4 5

ACOR Hedge Fund Activity: Q3 2019 in Review

151 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2019, worth a combined $157M — down 65% from $451M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of ACOR and 19 opened new positions — a net loss of 11 holders — while 42 trimmed existing stakes and 57 added.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $9.9M. The largest seller was State Street, cutting an estimated $11.1M.

  • 151 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2019, down from 163 in Q2 2019.
  • Funds reported $157M of Acorda Therapeutics stock for Q3 2019, down 65% quarter-over-quarter.
  • 19 funds opened new Acorda Therapeutics positions in Q3 2019 and 30 closed out, a net change of -11 holders.
  • The largest Acorda Therapeutics buyer in Q3 2019 was PFM Health Sciences, an estimated $9.9M added.
  • The largest Acorda Therapeutics seller in Q3 2019 was State Street, an estimated $11.1M sold.

Based on aggregated 13F filings for Q3 2019.